This Phase II study is a monocenter, long-term extension study of study GNC-401 and will
start after individual completion of Week 48 of the GNC-401 study. At entry, all patients
will receive active treatment with temelimab. The patients of the placebo group in study
GNC-401 will be re-randomized to temelimab 18 mg/kg, 36 mg/kg or 54 mg/kg (1:1:1), while the
patients who received temelimab in study GNC-401 will continue with the same dose in study
GNC-402. Following final analysis of the results of the GNC-401 study, the Sponsor may switch
all patients to an optimal dose of temelimab based on safety and efficacy demonstrated in the
GNC-401 study.